此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Chemotherapy-Minimized Blank Microsphere Transarterial Embolization (BMS-TACE) in Hepatocellular Carcinoma Resistant to FOLFOX-Based Hepatic Arterial Infusion Chemotherapy

2026年11月15日 更新者:Huang Jinhua、Sun Yat-sen University

Chemotherapy-Minimized, Blank Microsphere-Based Transarterial Chemoembolization (BMS-TACE) in Patients With BCLC Stage B/C Hepatocellular Carcinoma Resistant to FOLFOX-Based Hepatic Arterial Infusion Chemotherapy: A Single-Center, Single-Arm, Phase 2 Trial

FOLFOX-based hepatic arterial infusion chemotherapy (HAIC) is widely used for advanced hepatocellular carcinoma (HCC) in China, yet many patients show primary resistance or progress after an initial response, and no prospective trial has defined the optimal salvage strategy. This single-center, single-arm, phase 2 trial evaluates the efficacy and safety of chemotherapy-minimized, blank microsphere-based transarterial chemoembolization (BMS-TACE) in patients with BCLC stage B/C HCC resistant to FOLFOX-HAIC. In BMS-TACE, blank microspheres are the principal embolic agent and chemotherapy is used only as an adjunct at a minimal dose (low-dose pirarubicin in a small volume of lipiodol), in order to limit chemotherapy-related liver injury and systemic toxicity and to allow repeated embolization in patients with limited hepatic reserve. Forty-three participants will be enrolled using a Simon two-stage design. The primary endpoint is objective response rate by investigator assessment using mRECIST.

研究概览

研究类型

介入性

注册 (估计的)

43

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Guangdong
      • Guangzhou、Guangdong、中国、510060
        • 招聘中
        • Sun Yat-sen University Cancer Center
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 75年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Written informed consent
  • Age 18-75 years, any sex
  • Hepatocellular carcinoma confirmed by histology or cytology, or diagnosed clinically according to AASLD criteria
  • BCLC stage C, or BCLC stage B beyond the up-to-seven criteria
  • At least 4 prior cycles of FOLFOX-based hepatic arterial infusion chemotherapy (HAIC), with stable disease or progressive disease per RECIST 1.1 on contrast-enhanced CT or MRI performed 1-3 months after the last HAIC cycle
  • Portal vein, hepatic vein or inferior vena cava tumor thrombus and distant metastasis are permitted
  • Not a candidate for surgical resection as judged by the treating physician
  • Child-Pugh score ≤ 7
  • ECOG performance status 0-1
  • Adequate bone marrow function: absolute neutrophil count ≥ 1.5 × 10^9/L; hemoglobin ≥ 70 g/L; platelet count ≥ 50 × 10^9/L; white blood cell count ≥ 3.0 × 10^9/L
  • Adequate hepatic function: serum albumin ≥ 28 g/L; total bilirubin ≤ 3.0 mg/dL; AST and ALT ≤ 5 × upper limit of normal (ULN)
  • Adequate renal function: serum creatinine ≤ 1.5 × ULN
  • Adequate coagulation (not on anticoagulants): INR ≤ 2.3
  • Active hepatitis B virus infection: on antiviral therapy per local standard of care and willing to continue during the study
  • Hepatitis C virus antibody positive: on antiviral therapy per local standard of care and willing to continue during the study

Exclusion Criteria:

  • History of hypersensitivity or intolerance to any agent used in the study
  • Uncontrolled clinically significant ascites (not controlled by diuretics or paracentesis)
  • History of hepatic encephalopathy
  • Clinically significant gastrointestinal bleeding within 30 days before enrollment, or variceal bleeding within the past 3 months
  • Uncorrectable coagulopathy or marked hematological abnormality with evident bleeding tendency
  • Significant cardiovascular disease: congestive heart failure of NYHA class II or higher, unstable angina, myocardial infarction, or arrhythmia requiring medical treatment
  • History of congenital long QT syndrome, or corrected QT interval > 480 ms (Fridericia)
  • Left ventricular ejection fraction < 45%
  • Inadequately controlled hypertension (systolic > 150 mmHg and/or diastolic > 100 mmHg)
  • Urine protein ≥ 1 g/24 h (24-hour urine collection required if dipstick ≥ 1+)
  • Prior organ transplantation
  • Gastrointestinal malabsorption or any other condition that in the investigator's opinion may affect drug absorption
  • Active infection other than HBV or HCV
  • Other malignancy within the past 3 years or concurrent malignancy
  • Any other condition that in the investigator's opinion makes the patient unsuitable for the study

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:BMS-TACE

All participants receive chemotherapy-minimized, blank microsphere-based transarterial chemoembolization (BMS-TACE). Retreatment is performed on demand according to imaging every 6 weeks until progression, unacceptable toxicity, technical infeasibility, or withdrawal. Participants who were receiving anti-angiogenic therapy plus a PD-1/PD-L1 inhibitor concurrently with FOLFOX-HAIC continue the same regimen unchanged; participants who received FOLFOX-HAIC without systemic therapy do not start systemic therapy during the study. Other locoregional treatments (ablation, seed implantation) are not permitted unless the tumor is downstaged to allow curative treatment.

Visceral angiography of the celiac trunk, superior mesenteric artery and phrenic arteries maps the arterial supply of the tumor. A 2.8F microcatheter is placed super-selectively into each tumor-feeding artery by coaxial technique. A minimal-dose chemoemulsion (low-dose pirarubicin in a small volume of lipiodol) is injected first. Blank microspheres of any manufacturer are then delivered in ascending size order: 40-120 microns mixed with 5 mL contrast to occlude the distal tumor arterial bed; 100-300 microns for tumor arterial branches, with supplementary lipiodol emulsion if vascular lakes are seen; then 300-500 or 500-700 microns for the main feeding trunk. The endpoint is contrast stasis over 3-5 cardiac cycles with loss of at least 90% of intrahepatic tumor staining on completion angiography. Imaging is repeated every 6 weeks; retreatment follows protocol-defined criteria. Performed by one of two designated interventional radiologists.

其他名称:
  • bTACE
  • Blank microsphere embolization with low-dose chemotherapy

Low-dose pirarubicin emulsified with a small volume of lipiodol and injected intra-arterially into the tumor-feeding artery immediately before blank microsphere embolization, as the minimal-dose chemotherapy adjunct of each BMS-TACE session.

其他名称:
  • 热泵
  • Tetrahydropyranyl-adriamycin

Calibrated blank (non-drug-loaded) microspheres, 40-120, 100-300, 300-500 and 500-700 microns, of any manufacturer, delivered in ascending size order as the principal embolic agent in BMS-TACE.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Objective Response Rate (ORR) Per Modified Response Evaluation Criteria in Solid Tumors (mRECIST) as Assessed by Investigator
大体时间:From first BMS-TACE until disease progression, assessed after the first BMS-TACE and every 6 weeks thereafter (up to approximately 12 months)

ORR is defined as the proportion of participants whose best overall response from enrollment (first BMS-TACE) is complete response (CR) or partial response (PR) per mRECIST, as assessed by the investigator together with a senior radiologist. Tumor assessment by contrast-enhanced CT or MRI is performed after the first BMS-TACE and every 6 weeks (±7 days) thereafter, regardless of treatment delays, until progression, unacceptable toxicity, death, withdrawal of consent, loss to follow-up or study termination. Analysis population: full analysis set (all enrolled participants); participants without post-baseline assessment are counted as non-responders.

From first BMS-TACE until disease progression, assessed after the first BMS-TACE and every 6 weeks thereafter (up to approximately 12 months)

次要结果测量

结果测量
措施说明
大体时间
Progression-Free Survival (PFS) Per mRECIST as Assessed by Investigator
大体时间:From enrollment until progression or death (up to approximately 30 months)

PFS is defined as the time from enrollment (first BMS-TACE) to the first documented radiological progression per mRECIST or death from any cause, whichever occurs first. Participants alive without progression are censored at the date of last tumor assessment. Estimated by the Kaplan-Meier method.

From enrollment until progression or death (up to approximately 30 months)
Disease Control Rate (DCR) Per mRECIST as Assessed by Investigator
大体时间:From first BMS-TACE until disease progression, assessed after the first BMS-TACE and every 6 weeks thereafter (up to approximately 12 months)

Proportion of participants whose best overall response is CR, PR or stable disease (SD) per mRECIST, using the same assessment schedule as the primary outcome.

From first BMS-TACE until disease progression, assessed after the first BMS-TACE and every 6 weeks thereafter (up to approximately 12 months)
Duration of Response (DOR) Per mRECIST as Assessed by Investigator
大体时间:From first documented response until progression or death (up to approximately 30 months)

Among responders, the time from first documented CR or PR to first documented progression per mRECIST or death from any cause, whichever occurs first; responders without progression or death are censored at the last tumor assessment.

From first documented response until progression or death (up to approximately 30 months)
Overall Survival (OS)
大体时间:From enrollment until death from any cause (up to approximately 30 months)

OS is defined as the time from enrollment to death from any cause. Participants alive at last contact are censored at the date of last follow-up. Survival follow-up every 12 weeks (±7 days) after progression or start of new anticancer therapy, continuing until at least 12 months after the last participant's first BMS-TACE.

From enrollment until death from any cause (up to approximately 30 months)
Time to Untreatable Progression (TTUP)
大体时间:From enrollment until untreatable progression (up to approximately 30 months)

Time from enrollment to progression that precludes further BMS-TACE, including untreatable tumor progression and deterioration of liver function to Child-Pugh class C, as judged by the investigator. Participants still eligible for BMS-TACE are censored at last assessment.

From enrollment until untreatable progression (up to approximately 30 months)
Objective Response Rate (ORR) Per RECIST 1.1 as Assessed by Investigator
大体时间:From first BMS-TACE until disease progression, assessed after the first BMS-TACE and every 6 weeks thereafter (up to approximately 12 months)

Sensitivity analysis of the primary endpoint: proportion of participants with best overall response of CR or PR per RECIST 1.1, using the same assessment schedule.

From first BMS-TACE until disease progression, assessed after the first BMS-TACE and every 6 weeks thereafter (up to approximately 12 months)
Incidence and Severity of Adverse Events Per NCI CTCAE Version 5.0
大体时间:From first BMS-TACE until 30 days after last BMS-TACE (up to approximately 13 months)

Number and proportion of participants with treatment-emergent adverse events, serious adverse events and treatment-related adverse events, graded per NCI CTCAE v5.0, from first BMS-TACE until 30 days after the last BMS-TACE or start of new anticancer therapy, whichever is first. Safety set: all participants who receive at least one BMS-TACE.

From first BMS-TACE until 30 days after last BMS-TACE (up to approximately 13 months)

其他结果措施

结果测量
措施说明
大体时间
Change From Baseline in Quality of Life Per EORTC QLQ-C30
大体时间:Baseline, every 6 weeks during treatment, and end of treatment (up to approximately 12 months)

Change from baseline in health-related quality of life assessed with the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30). Scores for the global health status/quality of life scale, the five functional scales, and the symptom scales/items are linearly transformed to range from 0 to 100. Higher global health status/quality of life and functional scores indicate better quality of life or functioning; higher symptom scores indicate worse symptoms/problems. Change from baseline is calculated separately for each scale/item as the post-baseline score minus the baseline score.

Baseline, every 6 weeks during treatment, and end of treatment (up to approximately 12 months)
Change From Baseline in Quality of Life Per EORTC QLQ-HCC18
大体时间:Baseline, every 6 weeks during treatment, and end of treatment (up to approximately 12 months)

Change from baseline assessed with the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Hepatocellular Carcinoma Module (EORTC QLQ-HCC18). This 18-item module assesses fatigue, body image, jaundice, nutrition, pain, fever, abdominal swelling, and sexual interest. Each scale/item score is linearly transformed to range from 0 to 100; higher scores indicate worse symptoms/problems or poorer health-related quality of life. Change from baseline is calculated separately for each scale/item as the post-baseline score minus the baseline score.

Baseline, every 6 weeks during treatment, and end of treatment (up to approximately 12 months)

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Jinhua Huang, MD, PhD、Sun Yat-Sen University Cancer Center
  • 研究主任:Zhimei Huang, MD、Sun Yat-Sen University Cancer Center

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年10月20日

初级完成 (估计的)

2028年10月1日

研究完成 (估计的)

2029年3月1日

研究注册日期

首次提交

2026年10月9日

首先提交符合 QC 标准的

2026年11月15日

首次发布 (实际的)

2026年11月19日

研究记录更新

最后更新发布 (实际的)

2026年11月19日

上次提交的符合 QC 标准的更新

2026年11月15日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅